The Australian multinational biotech CSL is consolidating its research and development team, according to reporting from Fierce Biotech. The number of employees affected by the consolidation is unclear, though CSL said that more details would be shared at the company’s annual earnings call in August. According to comments made to Fierce, CSL will increasingly rely on external partnerships to bolster its pipeline. The reorganization comes just a month after the company got approval from the FDA for a preventive for attacks in patients with hereditary angioedema.
